Filing Flows › Nuo Therapeutics (AURX) › Q4 2024
Nuo Therapeutics (AURX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 1, 2025
Nuo Therapeutics (AURX) reported revenue of $395K for the fourth quarter 2024 (Q4 2024), +100% from a year earlier and +6% from the quarter before. Operating margin was -159.4%, net loss $497K (125.8% of revenue).
Nuo Therapeutics, Q4 2024: revenue $395K (+100% year over year), operating margin -159.4%, net loss $497K, operating cash flow −$491K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $395K | +6% | +100% |
| Operating profit | −$629K | — | — |
| Net earnings | −$497K | — | — |
| Operating cash flow | −$491K | — | — |
What changed
Revenue was $395K in Q4 2024, up 100% year over year and up 6% from the previous quarter.
Gross margin was 78.1%, down 0.9 points from a year earlier. Operating costs exceeded revenue by $629K, an operating margin of -159.4%. Operating expenses grew 16% against revenue growth of 100%. The quarter ended with a net loss of $497K, narrower than the previous quarter's $578K loss. Non-operating items added $133K, -27% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$491K. Non-cash charges added back $12K of depreciation and $30K of share-based compensation. Working capital and other items used $35K.
Questions
What was Nuo Therapeutics' revenue in the fourth quarter 2024?
Nuo Therapeutics (AURX) reported revenue of $395K for the fourth quarter 2024 (Q4 2024), +100% from a year earlier and +6% from the quarter before.
Was Nuo Therapeutics profitable in the fourth quarter 2024?
Operating loss was $629K (-159.4% of revenue) and net loss $497K.
Source: Nuo Therapeutics 10-K on SEC EDGAR.